Emergent BioSolutions Inc.

Total Valuation

Emergent BioSolutions Inc. carries a market capitalization of 320.41M, placing it among publicly traded companies globally. Its enterprise value stands at 871.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Emergent BioSolutions Inc. currently has 51.30M shares outstanding.

Valuation Ratios

Emergent BioSolutions Inc. trades at a trailing price-to-earnings ratio of 18.86. The price-to-sales ratio is 0.59, and the price-to-book ratio stands at 1.26.

Enterprise Valuation

On an enterprise value basis, Emergent BioSolutions Inc. trades at an EV/EBITDA multiple of 3.76 and an EV/FCF ratio of 5.10. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.34 provides insight into valuation relative to core operating earnings.

Financial Position

Emergent BioSolutions Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 170.42, indicating elevated leverage, while an interest coverage ratio of 4.56 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Emergent BioSolutions Inc. has paid 30.80M in income taxes, reflecting an effective tax rate of 60.36.

Stock Price Statistics

Emergent BioSolutions Inc.'s stock has declined approximately -18.61075% over the past 52 weeks. The 50-day moving average sits at 6.73, while the 200-day moving average is 9.05.

Income Statement

Over the trailing twelve months, Emergent BioSolutions Inc. generated 742.30M in revenue and converted that into -176.80M in net income, yielding earnings per share of -3.26. EBITDA reached 231.90M, while operating income came in at 137.50M.

Balance Sheet

Emergent BioSolutions Inc. holds 139.70M in cash and equivalents against 581.80M in total debt, resulting in a net debt position of 442.10M. Total book value stands at 341.40M, with working capital of 543.20M providing operational flexibility.

Cash Flow

Emergent BioSolutions Inc. produced 97.70M in operating cash flow over the past twelve months. After subtracting -11.80M in capital expenditures, free cash flow totaled 85.90M - equivalent to 1.64 per share.

Margins

Emergent BioSolutions Inc. operates with a gross margin of 54.21, reflecting its pricing power and cost economics. The operating margin of 18.52 and net profit margin of -23.82 provide insight into operational efficiency.

Dividends & Yields

Scores

Emergent BioSolutions Inc. posts an Altman Z-Score of 1.95, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.